He added that the drug received the FDA approval on June 17 after the company had applied for the green-light in 2019.
Clinical trials had commenced last year.
“Soaanz is specifically formulated to reduce excessive urination in heart failure patients,” Shah, a resident of Vienna, Virginia, told the American Bazaar.
“We believe that for many of these patients who are aged 65 and older, the new treatment option now approved by the FDA offers tremendous benefits.”
According to the US Centers for Disease Control and Prevention, heart failure affects nearly 1.8 per cent of the country’s population, or about 5.7 million Americans.
Source: IANS
